Ocugen

OCGN · NASDAQ

$0.8125+$0.0252 (+3.20%)TodayMarket closed · Oct 20, 7:55 PM ET

Prev close $0.7873

OCGN analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $12.41 (+1427.4% upside)

Low: $8.08
Now: $0.8125
High: $23.10

Upgrades and downgrades

The latest rating actions, newest first

OCGN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 10, 2026	Maintains	Buy	$10.00 → $9.50	43%
Canaccord Genuity	May 27, 2026	Maintains	Buy	$12.00 → $11.00	41%
Chardan Capital	Mar 25, 2026	Maintains	Buy	$7.00	54%
HC Wainwright & Co.	Mar 25, 2026	Maintains	Buy	$7.00 → $10.00	43%
Canaccord Genuity	Mar 17, 2026	Initiates	Buy	$12.00	41%
Oppenheimer	Mar 11, 2026	Initiates	Outperform	$10.00	45%
Chardan Capital	Mar 5, 2026	Maintains	Buy	$7.00	54%
Chardan Capital	Jan 20, 2026	Maintains	Buy	$7.00	54%

The case for and against

Updated Oct 21, 2026

Bull case

Ocugen is supported by improved liquidity and multiple funding levers, with the recent debt offering extending runway into 2028 and net proceeds of about $80M after retiring Avenue debt. It also has additional balance-sheet flexibility from outstanding Janus Henderson warrants that could add roughly $50M if exercised, plus a Priority Review Voucher for Stargardt that it expects to monetize. Fundamentally, the investment case is strengthened by its diversified pipeline in retinal, regenerative, and vaccine platforms, alongside ongoing partnership discussions that could provide non-dilutive funding.

Bear case

Ocugen is facing a more cautious fundamental outlook because the September 3, 2026 interim analysis of GARDian3 showed a negative direction of treatment effect in 26 of 63 enrolled subjects and raised the possibility of futility, even as the DMC asked for additional 8-month follow-up to resolve a baseline lesion-size imbalance. The company’s valuation remains highly dependent on unproven gene therapy assets, while regulatory timing may slip beyond 2028 and management has not yet disclosed its strategy, increasing clinical and execution uncertainty. With a challenging financing environment, net debt of $17.7M, and meaningful regulatory, commercial, manufacturing, and IP risks, the path to monetizing the pipeline looks increasingly fragile.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.